Meeting
2016 Gastrointestinal Cancers Symposium
Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
Authors
Richard Tuli
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
Richard Tuli , Nicholas N. Nissen , Alagappan Annamalai , David M. J. Hoffman , Miranda Bryant , Mourad Tighiouart , Andre Rogatko , Sepehr Rokhsar , Kevin S. Scher , Laith Jamil , Simon Lo , Andrew Eugene Hendifar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01908478
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS487)
DOI
10.1200/jco.2016.34.4_suppl.tps487
Abstract #
TPS487
Poster Bd #
O15
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer.
First Author: Kyle Clifford Cuneo
Poster
2012 ASCO Annual Meeting
A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.
First Author: Jean-Luc Van Laethem
Poster
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
First Author: Deborah Kay Armstrong
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen